Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Eventsa
Advertisement
aEditor’s Note: References to these tools are provided for educational purposes only. Terms of use for these tools may vary and some may be subject to copyright restrictions.
Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)
Patient Completed mcAEs Specific Symptom Experience Diary for Targeted Therapies
Skindex-16 and Hair Specific Skindex-29
Related Articles
How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life
Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous ...